CA Patent

CA2991096A1 — Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Assigned to Acerta Pharma BV · Expires 2017-01-05 · 9y expired

What this patent protects

The present disclosure relates to crystalline solid forms of (S)-4-(8-amino-3-(l-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[ 1,5-a ]pyrazin-l-yl)-N( pyridin-2-yl)benzamide, and hydrates and salts thereof. The present disclosure further relates to use of the crystalline solid forms of t…

USPTO Abstract

The present disclosure relates to crystalline solid forms of (S)-4-(8-amino-3-(l-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[ 1,5-a ]pyrazin-l-yl)-N( pyridin-2-yl)benzamide, and hydrates and salts thereof. The present disclosure further relates to use of the crystalline solid forms of the present disclosure in the treatment of diseases.

Drugs covered by this patent

Patent Metadata

Patent number
CA2991096A1
Jurisdiction
CA
Classification
—
Expires
2017-01-05
Drug substance claim
No
Drug product claim
No
Assignee
Acerta Pharma BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.